After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
As many as eight companies are expected to price their IPOs in the upcoming week, including three larger deals. BKV (BKV) plans to raise $300 million at a $1.7 billion market cap. The company is primarily focused on natural gas production in the Barnet Shale ...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
Biotech IPOs are back: Why 2026 could mark a hot year for the sector
After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
US IPO Week Ahead: Natural gas producer leads week with three sizable IPOs
As many as eight companies are expected to price their IPOs in the upcoming week, including three larger deals. BKV (BKV) plans to raise $300 million at a $1.7 billion market cap. The company is primarily focused on natural gas production in the Barnet Shale ...read more